

Special Issue

Vaccination Against Vector-Borne Diseases: Bridging Public Health and Epidemiology

Message from the Guest Editors

This Special Issue aims to focus on the recent advancements in vaccine development, including novel vaccine candidates and technologies **targeting vector-borne pathogens**. Emphasis is placed on how epidemiological data can inform vaccine deployment, maximizing the impact of immunization programs within vulnerable communities and high-risk regions. Articles within this Special Issue should also examine public health frameworks, discussing how surveillance systems, community engagement, and health education can be strengthened to support vaccination efforts.

This Special Issue also aims to **address factors which influence vector-borne diseases that require adaptive vaccination strategies**. Overall, this Special Issue aims to showcase how vaccines, when integrated with robust public health and epidemiological frameworks, offer a powerful tool to reduce the burden of diseases worldwide.

Guest Editors

Dr. Angela Stufano

DIM Section of Occupational Medicine "EC Vigliani", Università degli studi di Bari Aldo Moro, 70121 Bari, Italy

Dr. Claudia Maria Trombetta

Department of Molecular and Developmental Medicine, University of Siena, Banchi di Sotto, 55, 53100 Siena, Italy

Deadline for manuscript submissions

closed (31 August 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/224580

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).